Advertisement.

SLRN Projected Dividend Yield

ACELYRIN Inc ( NASDAQ : SLRN )

ACELYRIN is engaged in the identification, acquisition, development and commercialization of medicines for autoimmune and inflammatory diseases. Co.'s clinical and preclinical stage product candidates consisting of: izokibep, which is a small protein therapeutic designed to inhibit anti-interleukin-17A; lonigutamab, which is a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor for the treatment of chronic urticaria; and SLRN-517, which is a fully human IgG1 monoclonal antibody targeting c-KIT for the treatment of chronic urticaria.

20 YEAR PERFORMANCE RESULTS

SLRN Dividend History Detail
SLRN Dividend News
SLRN Competitors News

# of Shares: 0

Closing Price: 3.23

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000